Carv­ing a pipeline out of trou­bled Te­va, Or­biMed leads $60M launch of new NASH play­er

Te­va $TE­VA has had a rough year. Plagued by crip­pling debt, the Is­raeli gener­ics gi­ant has un­der­gone a mas­sive reck­on­ing that cul­mi­nat­ed in an ex­ec­u­tive ex­o­dus and a re­or­ga­ni­za­tion of the busi­ness. Mat­ters went from bad to worse ear­li­er this month when its mi­graine drug that was pegged to re­vive its for­tunes was snubbed by US phar­ma­cy ben­e­fit man­ag­er Ex­press Scripts $ES­RX in fa­vor of ri­val treat­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.